BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience was written by Stefoni, Vittorio;Argnani, Lisa;Carella, Matteo;Casadei, Beatrice;Morigi, Alice;Lolli, Ginevra;Broccoli, Alessandro;Pellegrini, Cinzia;Nanni, Laura;Coppola, Paolo Elia;Zinzani, Pier Luigi. And the article was included in Journal of Cancer Research and Clinical Oncology.HPLC of Formula: 16506-27-7 The following contents are mentioned in the article:
One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT). Finding a salvage regimen able to induce this status without severe toxicity would represent a major achievement in this setting. A single-center retrospective study was conducted to assess effectiveness and safety of BEGEV (bendamustine, gemcitabine, and vinorelbine) regimen as first salvage setting prior to ASCT in HL patients. Forty-three patients were treated in our institution between Oct. 2017 and Nov. 2020. Median age at BEGEV therapy was 35.0 years (range 17.2- 70.0), and the median time from frontline therapy to the first cycle of BEGEV was 79.5 days (range 4-2267). At the end of treatment, 31 patients achieved a complete response (CR), with an overall response rate of 76.7%. Forty-one patients harvested CD34+ cells and 35/43 (81.4%) patients underwent ASCT. With a median follow-up of 22 mo, 4 CR patients had disease relapse, yielding an estimated disease-free survival of 73.9% at 34 mo. The estimated 2-yr progression-free survival was 66.7%. Response to first-line chemotherapy did not significantly influence prognosis. BEGEV regimen was well tolerated, and reversible haematol. toxic effects were the most common adverse events. Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7HPLC of Formula: 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.HPLC of Formula: 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem